James Mandell is Director at bluebird bio, Inc. (BLUE). They have made 6 open-market trades across 1 company since 2015, most recently 2018-09-10.
CIK 0001595896
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BLUE | 1,000 | $5K |
Shares reported on the most recent Form 4, priced at the 2018-09-12 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLUE | SELL | 2018-09-10 | 2018-09-12 | $150.73 | $291K | -6.1% | -15.1% | -29.4% |
| BLUE | SELL | 2017-08-14 | 2017-08-15 | $95.95 | $96K | +0.6% | +35.5% | +58.8% |
| BLUE | SELL | 2017-02-15 | 2017-02-17 | $80.22 | $84K | +12.0% | +17.8% | +13.9% |
| BLUE | SELL | 2017-02-14 | 2017-02-16 | $80.01 | $952K | +21.5% | +19.8% | +12.7% |
| BLUE | SELL | 2017-01-31 | 2017-02-02 | $75.04 | $600K | +3.0% | +8.4% | +13.3% |
| BLUE | SELL | 2017-01-27 | 2017-01-31 | $70.10 | $351K | +1.4% | +16.5% | +21.4% |
| BLUE | SELL · 10b5-1 | 2015-09-01 | 2015-09-03 | $125.96 | $189K | -26.5% | +1.0% | +1.0% |
| BLUE | SELL · 10b5-1 | 2015-08-10 | 2015-08-12 | $148.44 | $223K | -26.5% | +1.0% | +1.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.